Thymosin Beta-4
Also known as: TB-4, Tβ4, Timbetasin
The full 43-amino acid protein that TB-500 is derived from. Naturally occurring in most human tissues, TB-4 has a shorter half-life (~2 hours) compared to its synthetic fragment TB-500 (~2-4 days). Often mislabeled as 'TB-500' by vendors in premixed products.
Mechanism of Action
Thymosin Beta-4 is the primary actin-sequestering protein in mammalian cells. It regulates actin polymerization, promotes cell migration, angiogenesis, and wound healing. TB-4 also has anti-inflammatory properties and promotes stem cell differentiation. The active healing region of TB-4 was isolated to create the synthetic fragment TB-500.
Research Summary
Extensive research on wound healing, cardiac repair, and tissue regeneration. Studies show TB-4 accelerates dermal wound closure and promotes corneal epithelial healing. Research in cardiac repair shows improved outcomes post-myocardial infarction in animal models. The shorter half-life means more frequent dosing compared to TB-500.
Research Protocols
Note: Doses observed in research studies - more frequent dosing required than TB-500 due to shorter half-life
Common Doses
Duration
4-8 weeks typical protocol
Administration
Subcutaneous injection, topical for eye conditions
Timing & Administration
HealingAs a Healing peptide: Morning or split doses is the recommended administration time.
Best Time to Take
Morning or split doses
Daily or every other day due to short half-life
Food Recommendation
either
Why This Timing?
Based on mechanism of action: Due to short ~2 hour half-life, some protocols use multiple daily doses. Timing is flexible but consistency is important.
Timing recommendations are based on pharmacological principles and mechanism of action, not dedicated clinical trials on administration timing. Most peptide studies focus on efficacy rather than optimal timing. Consult a healthcare provider for personalized guidance.
Side Effects & Considerations
- ●Generally well-tolerated
- ●Injection site reactions
- ●Headache
- ●Fatigue
- ●May trigger histamine release - use caution with MCAS or histamine sensitivity
- ●Theoretical concern for cancer cell motility
- ●Contraindicated with active cancer
- ●Limited long-term safety data
References
Want updates on Thymosin Beta-4 research?
Subscribe to get notified when we add new research findings, protocol updates, and related peptide information.
Educational Information Only
This information is provided for educational purposes only and is not intended as medical advice. Always consult with qualified healthcare providers before making any decisions about peptides or other substances. The protocols listed reflect doses observed in research studies, not recommendations.